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Purpose: To investigate added morbidity associated with the addition of pelvic elective nodal irradiation (ENI) to
hypofractionated radiotherapy to the prostate.
Methods and materials: Two-hundred twelve patients, treated with hypofractionated radiotherapy to the prostate
between 2004 and 2011, met the inclusion criteria for the analysis. All patients received 70 Gy to the prostate
delivered over 28 fractions and 103 (49%) received ENI consisting of 50.4 Gy to the pelvic lymphatics delivered
simultaneously in 1.8 Gy fractions. The mean dose-volume histograms were compared between the two subgroups
defined by use of ENI, and various dose-volume parameters were analyzed for effect on late lower gastrointestinal
(GI) and genitourinary (GU) toxicity.
Results: Acute grade 2 lower GI toxicity occurred in 38 (37%) patients receiving ENI versus 19 (17%) in those who
did not (p = 0.001). The Kaplan-Meier estimate of grade≥ 2 lower GI toxicity at 3 years was 15.3% for patients receiving
ENI versus 5.3% for those who did not (p = 0.026). Each rectal isodose volume was increased for patients receiving ENI
up to 50 Gy (p≤ 0.021 for each 5 Gy increment). Across all patients, the absolute V70 of the rectum was the only
predictor of late GI toxicity. When subgroups, defined by the use of ENI, were analyzed separately, rectal V70 was only
predictive of late GI toxicity for patients who received ENI. For patients receiving ENI, V70 > 3 cc was associated with an
increased risk of late GI events.
Conclusions: Elective nodal irradiation increases the rates of acute and late GI toxicity when delivered simultaneously
with hypofractioanted prostate radiotherapy. The use of ENI appears to sensitize the rectum to hot spots, therefore we
recommend added caution to minimize the volume of rectum receiving 100% of the prescription dose in these patients.
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Multiple clinical trials have shown improved biochemical
control of clinically localized prostate cancer with in-
creased radiation doses [1-3]. Unfortunately, these dose-
escalation regimens have been associated with increased
rates of late toxicity, with late rectal toxicity increased
two-fold in one early phase III trial [1]. Improvements in* Correspondence: ammcdonald@uabmc.edu
1University of Alabama at Birmingham Department of Radiation Oncology,
1700 6th Avenue, South Birmingham, AL 35249, USA
Full list of author information is available at the end of the article
© 2014 McDonald et al.; licensee BioMed Cen
Creative Commons Attribution License (http:/
distribution, and reproduction in any medium
Domain Dedication waiver (http://creativecom
article, unless otherwise stated.treatment planning and delivery, such as intensity-
modulated radiotherapy (IMRT) and image-guided radio-
therapy (IGRT), have helped to decrease the rate of
adverse effects compared to conventional techniques [4,5].
Hypofractionation has also been suggested as a means of
achieving a higher biologically effective dose (BED) with-
out leading to increased late toxicity rates.
A growing body of evidence suggests that the biologic
response of prostate cancer to larger fraction size ex-
ceeds that of the surrounding normal tissues, with the
majority of published α/β estimates less than 3 Gy [6,7].tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
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fractionation in order to improve the therapeutic ratio of
prostate cancer radiotherapy. By increasing the fraction
size and decreasing total dose, an equivalent BED may
be delivered to the prostate while decreasing the BED to
surrounding normal tissues. Multiple retrospective and
phase I/II experiences with moderately hypofractionated
regimens (2.5 – 3.0 Gy per fraction) suggest encouraging
estimates of biochemical control and toxicity [8-10] and
one phase III trial has been reported [11].
Conventionally fractionated pelvic irradiation concur-
rent with hypofractionated prostate irradiation has been
shown to be both feasible and well-tolerated [10,12,13]
though any additional morbidity associated these lymph-
atic treatment volumes has not been quantified. Our
preliminary outcomes suggested that the addition of
elective nodal irradiation (ENI) was associated with a
statistically significant increase in late rectal toxicity
[14]. In this work we sought to further explore any asso-
ciation between ENI and increased toxicity. We sought
to characterize differences in dose-volume parameters
associated with toxicity which could aid future treatment
plan generation and evaluation.
Methods and materials
Inclusion criteria
The records of all patients receiving external beam
radiotherapy for clinically localized prostate cancer since
2004 were reviewed. All patients who received 70 Gy to
the prostate delivered over 28 fractions and who had at
least 1 year of clinical follow-up were included in the
analysis. The study was approved by the University of
Alabama at Birmingham institutional review board.
Simulation and structure definitions
All patients underwent CT simulation in the supine pos-
ition with a custom immobilization device. Patients were
asked to have a full bladder and an empty rectum; if a
large quantity of stool was noted in the rectum then
patients were resimulated after attempting a bowel
movement.
Normal structures contoured for all patients include
the femoral heads, bladder, rectum, and bowel space su-
perior to the rectum. The bladder was contoured as a
solid organ. The rectum was also contoured as a solid
organ from the level of the ischial tuberosities inferiorly
to the level of the rectosigmoid junction. Above the level
of the rectosigmoid junction the entire peritoneal con-
tents were contoured as one structure.
Three distinct clinical target volumes (CTVs) were de-
fined. The prostate, along with any visible areas of tumor
extension, was contoured as the CTVP. The entire sem-
inal vesicles were contoured as the CTVSV. The CTVLN
was generated as a 7 mm uniform expansion around theinternal, external, and common iliac vessels. In general,
the iliac vessels were countoured to the L5-S1 junction
superiorly, though this was somewhat variable. The
planned target volumes (PTVs) for the prostate and sem-
inal vesicles, PTVP and PTVSV, were generated similarly
as a 7 mm expansion around the respective CTV except
for posteriorly where the expansion was [4,5] mm. The
PTVLN was generated by expanding the CTVLN [5-10]
mm at the discretion of the treating physician.
Plan generation and evaluation, treatment delivery, and
androgen deprivation
Patients with NCCN low-risk disease were prescribed
70 Gy to the PTVP only. High-risk patients and inter-
mediate risk patients with 10% or greater risk of lymph
node involvement by Partin tables [15] were prescribed
70 Gy to the PTVP, 56 Gy to the PTVSV, and 50.4 Gy to
the PTVLN. The remaining patients were prescribed
70 Gy to the PTVP and 56 Gy to the PTVSV. All pre-
scription doses were delivered simultaneously over 28
fractions.
Treatment plans were generated by either Varian Eclipse
or TomoTherapy treatment planning software. Eclipse
plans were required to deliver 95% of the prescription
dose to the entire PTV and TomoTherapy plans were re-
quired to deliver the entire prescription dose to 95% of
the PTV. Plans generated in Eclipse utilized either static
beam IMRT or volumetric modulated arc therapy (VMAT).
A number of dose-volume parameters were used as guide-
lines for plan generation and the current iteration of our
institutional guidelines is included in Table 1. The only
constraint weighted higher than PTV coverage was rectal
V70 < 10 cc based on the work by Kupelian et al. with this
fractionation regimen [8].
Treatment was delivered by a TomoTherapy, Varian
2100 series, or Varian TrueBeam linear accelerator. CT-
based image guidance with alignment to the prostate-
rectum interface was performed prior to the delivery of
each fraction.
Patients with intermediate and high-risk disease also
received androgen deprivation therapy (ADT) unless
they specifically declined this aspect of treatment. ADT
consisted of a LHRH analog with an initial short course
of anti-androgen. This was begun at least 2 months prior
to the start of RT with a total planned duration of
6 months for intermediate-risk patients and 2–3 years
for high-risk patients.
Endpoint definition and follow-up
Patients were scheduled for follow-up visits every
4 months for the first year, every 6 months for an add-
itional 4 years, and annually thereafter. Patients were
assessed for toxicity at each visit according to the Com-
mon Terminology Criteria for Adverse Events version
Table 1 Current dosimetric guidelines and isodose volumes
stratified by ENI
Goal1 No ENI ENI p2
Rectum Mean (±SD)
V70 <10 cc
3 2.1 cc (±1.5 cc) 2.4 cc (± 2.0 cc) 0.369
V60 <10 cc
4 8.3 cc (±4.2 cc) 9.2 cc (±5.0 cc) 0.158
V50 <17%
4 19.5% (±9.1%) 23.0% (±10.6%) 0.021
V30 <35%
4 53.6% (±20.0%) 69.8% (±21.4%) <0.001
Bladder
V60 <10%
4 12.1% (±10.1%) 13.4% (±10.8%) 0.197
V50 <25%
4 20.5% (±15.2%) 27.1% (±15.7%) <0.001
V30 <50%
4 47.2% (±28.0%) 72.9% (±25.5%) <0.001
1Current guidlines; treatment planning goals have become more strict since
initially implemented. 2Independent samples Kruskal-Wallis test. 3Prioritized
greater than PTV coverage. 4Planning goal but less important than PTV coverage.
Bolded text indicates a statistically significant difference.
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each patient was taken into account for the analysis.
Late toxicity was considered any new toxicity occurring
3 or more months from the completion of RT. Early tox-
icity which did not resolve within 3 months of the com-
pletion of RT was scored as early toxicity only.
Statistical methods
Patients were stratified based on whether or not they re-
ceived treatment to the pelvic lymph nodes. Means
between the two groups were compared using the inde-
pendent samples T-test and Kruskal-Wallace independ-
ent samples test; frequencies were compared using the
Pearson χ2 test. Estimates of late toxicity were calculated
by the Kaplan-Meier method and comparison between
groups was by the log-rank test. Dose-volume parame-
ters were tested within each group for effect on toxicity
by univariate Cox regression modeling. For dose-volume
parameters that were statistically significant by Cox re-






Age at start of RT 6
Prostate volume (cc) 5
Rectum volume (cc) 9
Bladder volume (cc) 22
1Person χ2 test. 2Independent samples T-test. Bolded text indicates a statistically sigvolume which maximized the discriminatory ability of a
receiver-operating characteristic (ROC) curve.
Given that analyzing dose-volume parameters may
only predict outcome when above a particular threshold
value, ROC curves were generated for each variable
which was not statistically significant by Cox regression.
A variable was required to generate a c-statistic of 0.7 or
higher to be considered a good predictor of outcome.Results
Pretreatment and treatment characteristics
A total of 212 patients were included in the analysis. Of
the 243 patients treated with this regimen since 2004, 24
were excluded due to inadequate clinical follow-up and
7 treatment plans were unable to be unarchived due to
data corruption errors. Median follow-up was 33 months
(range 13–96 months). Pelvic lymph nodes were treated
in 103 (49%) patients. A table of pretreatment and treat-
ment characteristics is presented as Table 2. Nearly all
patients receiving ENI also received concurrent ADT
compared to less than half of those not receiving ENI.
There was a trend towards a larger prostate volume and
a higher proportion of VMAT plans within the group
not receiving ENI.Acute toxicity
No patient experienced grade 3 or higher acute toxicity.
Acute grade 2 lower GI toxicity occurred in 38 (37%) pa-
tients receiving ENI and in 19 (17%) of those that did
not (p = 0.001). Grade 2 lower GI toxicity consisted of
diarrhea or rectal bleeding that resolved with medical
therapy. Acute grade 2 genitourinary toxicity occurred
in 54 (52%) of patients receiving ENI and 52 (48%) of
those that did not (p = 0.492). Grade 2 genitourinary tox-
icity consisted of dysuria or hesitancy that resolved with
medical therapy. No patient experienced delay or ter-
mination of treatment due to acute toxicity.ENI (109) ENI (103) p
Frequencies1 (%)
47 (43%) 47 (46%) 0.081
22 (20%) 28 (28%)
40 (37%) 28 (27%)
44 (40%) 98 (95%) <0.001
Means2 (±SD)
7.5 (±8.5) 67.1 (±7.8) 0.631
3.4 (±29.8) 46.2 (±24.3) 0.055
2.9 (±53.5) 98.0 (±47.5) 0.467
7.7 (±147.4) 206.2 (±164.2) 0.317
nificant difference.
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No patient experienced a grade 4 late toxicity event. The
Kaplan-Meier estimate of grade ≥ 2 lower GI toxicity
(Figure 1a) at 3 years was 15.3% for patients receiving
ENI and 5.3% for those who did not (p = 0.026). A Cox
regression model yielded a hazard ratio of 3.023 [1.089 –
8.392] associated with the addition ENI. The Kaplan-
Meier estimate of grade 3 GU toxicity (Figure 1b) at
3 years was 6.7% for patients receiving ENI and 8.6% for
those that did not (p = 0.918). Details of late toxicity
events are presented as Table 3.
Dose-volume histogram (DVH) analysis
The mean bladder and rectal DVHs are presented as
Figure 2. Each bladder isodose volume was increased for
patients receiving ENI up to the level of 55 Gy (p ≤ 0.027
for each 5 Gy increment). Each rectal isodose volume
was increased for patients receiving ENI up to 50 Gy
(p ≤ 0.021 for each 5 Gy increment).
Various dose-volume parameters were evaluated for effect
on late toxicity (Table 4). ENI and absolute V70 were shown
to have a statistically significant effect on late lower GI tox-
icity. No parameter was shown to have an effect on late GU
toxicity and no additional parameter was associated with
c ≥ 0.7 on ROC analysis for either GI or GU toxicity.
Given the statistically different DVH curves associated
with the addition of ENI, we repeated the analysis strati-
fied by the use of ENI. For patients receiving ENI, both
rectal volume and the absolute V70 of the rectum were
predictive of late lower GI toxicity. The percent V40 of
the bladder was predictive of late GU toxicity for pa-
tients receiving ENI. No parameter was predictive of ei-
ther GI or GU toxicity for patients not receiving ENI.
The cut-points generated for rectal V70 and bladder V40
were 3 cc and 50%, respectively. The Kaplan-Meier plots
of rectal and bladder toxicity stratified by these cut-
points and ENI are presented as Figure 3.Figure 1 Kaplan-Meier estimates of late grade ≥ 2 lower GI toxicity (aDiscussion
Data regarding the morbidity of adding conventionally
fractionated ENI to hypofractionated prostate radiother-
apy remains sparse. A recent review of the literature
identified 8 studies with a combined total of 374 patients
treated in this manner; however, no study directly ad-
dressed to what extent adding ENI increased toxicity
[17]. We performed this retrospective study in order to
further elucidate the additional toxicity of adding ENI to
a hypofractionated regimen and which, if any, dosimetric
parameters were predictive of these events. We found
the addition of ENI to be associated with increased the
rates of both acute and late grade ≥ 2 lower GI toxicity.
The rates of GU toxicity were not increased when ENI
was utilized.
Comparison of the toxicity rates in our study to the
only published large-scale phase III trial of hypofractio-
nation which included treatment to the pelvic lymph
nodes in a subset of patients is difficult, as the data has
not yet been reported stratified by treatment of the pelvic
lymph nodes [11]. Additionally, moderate hematuria re-
quiring cystoscopy and urethral stricture requiring dilata-
tions were scored as grade 2 GU events by Pollack et al.
whereas we scored such events as grade 3. With this in
mind, the rates of late GI and GU toxicity across all pa-
tients in our analysis appear similar to those reported in
this trial with respect to the revised protocol definition of
GU toxicity. This trial did show nodal irradiation to be as-
sociated with worse GU outcomes on multivariate analysis
whereas we did not observe this effect. The rates of tox-
icity in our study also fall within the ranges reported by
other phase II and retrospective studies [8-10,12,13].
That ENI was associated with increased late rectal tox-
icity in our study is not altogether surprising given that
the whole-pelvic RT plus neoadjuvant ADT (WRPT +
NHT) arm of RTOG 94–13 was associated with in-
creased rates of late grade ≥ 3 rectal toxicity [18]. In) and late grade 3 GU toxicity (b).
Table 3 Details of late toxicity events stratified by ENI
No ENI (109) ENI (103)
Grade 2 GI events Diarrhea Endoscopic evidence of proctitis 1 (1%) 0
Endoscopy not performed 1 (1%) 1 (1%)
Endoscopic evidence of proctitis 1 (1%) 4 (4%)
Grade 3 GI events Rectal bleeding Required endoscopic laser coagulation procedure 1 (1%) 1 (1%)
Required blood transfusion 0 1 (1%)
Grade 3 GU events Urethral stricture requiring dilation 3 (3%) 4 (4%)
Gross hematuria 4 (4%) 5 (5%)
Chronic cystitis requiring long-term catheterization 1 (1%) 0
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dose-escalation may magnify this effect and IMRT may
mitigate it. These questions and others will be explored by
the ongoing RTOG 09–24 trial which will further clarify
the role of ENI in the conventionally fractionated setting,




































Figure 2 Mean rectal (a) and bladder (b) dose-volume histograms. Th
the two curves.In terms of dosimetry, the rectal isodose volumes up
to the level of 50 Gy were increased for patients receiv-
ing ENI. Given the increased lower GI toxicity in pa-
tients receiving ENI, we were surprised to find that no
isodose volume was predictive of late rectal toxicity
where the two DVHs differed. Instead, V70 was the only55 65 75
No ENI
ENI
5 55 65 75
No ENI
ENI
e shaded region indicates a statistically significant difference between
Table 4 Analysis of dose-volume parameter effect on late toxicity
All (212) ENI (103) No ENI (109)
HR [95% CI] p HR [95% CI] p HR [95% CI] p
GU
Bladder volume 0.996 [0.991 – 1.001] 0.154 0.996 [0.989 – 1.004] 0.353 0.996 [0.988 – 1.003] 0.242
Bladder mean dose 1.000 [1.000 – 1.001] 0.186 1.001 [1.000 – 1.001] 0.059 1.000 [0.999 – 1.001] 0.945
V40 (percent) 1.016 [0.996 – 1.036] 0.119 1.032 [1.003 – 1.062] 0.029 0.964 [0.908 – 1.023] 0.228
V60 (percent) 1.021 [0.988 – 1.056] 0.205 1.029 [0.990 – 1.069] 0.150 0.992 [0.828 – 1.188] 0.931
V60 (percent) 1.034 [0.974 – 1.098] 0.270 1.044 [0.975 – 1.118] 0.213 1.166 [0.820 – 1.656] 0.955
V40 (absolute) 1.007 [0.968 – 1.047] 0.849 1.001 [0.992 – 1.011] 0.806 1.001 [0.980 – 1.022] 0.616
V60 (absolute) 1.007 [0.968 – 1.047] 0.733 1.002 [0.953 – 1.053] 0.939 1.017 [0.952 – 1.087] 0.616
V70 (absolute) 1.016 [0.944 – 1.094] 0.616 1.007 [0.917 – 1.106] 0.877 1.031 [0.909 – 1.170] 0.631
ADT 0.193 - 1.647 [0.805 – 3.367] 0.172
ENI 1.517 [0.810 – 2.841] 0.193 -
Volume of PTVLN - 1.002 [0.998 – 1.006] 0.245 -
GI
Rectum volume 1.001 [0.999 – 1.011] 0.081 1.009 [1.002 – 1.016] 0.017 0.973 [0.934 – 1.014] 0.196
Rectum mean dose 1.000 [0.999 – 1.001] 0.401 0.999 [0.999 – 1.000] 0.187 1.000 [0.999 – 1.001] 0.769
V40 (percent) 0.993 [0.967 – 1.021] 0.632 0.983 [0.952 – 1.015] 0.287 0.997 [0.938 – 1.059] 0.923
V60 (percent) 0.950 [0.847 – 1.065] 0.376 0.968 [0.861 – 1.089] 0.588 0.905 [0.706 – 1.163] 0.439
V70 (percent) 1.049 [0.827 – 1.332] 0.692 1.057 [0.814 – 1.374] 0.676 1.033 [0.621 – 1.718] 0.901
V40 (absolute) 1.011 [0.996 – 1.026] 0.158 1.011 [0.995 – 1.028] 0.183 0.959 [0.882 – 1.042] 0.319
V60 (absolute) 1.049 [0.962 – 1.143] 0.282 1.077 [0.989 – 1.173] 0.087 0.796 [0.598 – 1.060] 0.119
V70 (absolute) 1.249 [1.008 – 1.548] 0.042 1.314 [1.047 – 1.648] 0.018 0.778 [0.390 – 1.551] 0.476
ADT 1.199 [0.719 – 2.000] 0.486 1.548 [0.633 – 3.788] 0.338
ENI 3.023 [1.089 – 8.392] 0.034 - 1.548 [0.633 – 3.788] 0.338
Volume of PTVLN - 0.999 [0.996 – 1.002] 0.426 -
Bolded text indicates a statistically significant difference.
Figure 3 Kaplan-Meier estimates of late grade ≥ 2 lower GI toxicity (a) and late grade 3 GU toxicity (b) stratified by ENI and isodose
volume cut-points.
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creased toxicity across the entire cohort of patients.
When the two groups were analyzed separately, V70 was
only predictive of toxicity for patients receiving ENI,
though the absolute V70 was not statistically different be-
tween the two groups. Furthermore, the effect of the V70
within the ENI group seemed to be driving the effect
within the population as a whole. These results suggest
that increased volumes of the rectum receiving low and
moderate doses decreases the tolerance of the rectum to
hot spots in terms of developing clinically apparent toxicity.
That V70 was not a predictor of rectal toxicity for pa-
tients who did not receive ENI is likely a result of the
fact that V70 < 8 cc for all patients in our analysis. With
10 cc being the previously reported volume at which in-
creased risk of toxicity for patients not receiving ENI
was observed [8], the threshold for observing this effect
was simply not met in our study.
Mean bladder isodose volumes were increased in pa-
tients receiving ENI up to the level of 55 Gy. Despite
this, the rate and type of late GU toxicity was nearly
identical between the two groups. With this in mind we
expected to find predictors of toxicity above 55 Gy,
where the isodose distributions did not differ. However,
no dose-volume parameters were found to be predictive
of GU toxicity across all patients when analyzed as con-
tinuous variables. When the group receiving ENI was
analyzed separately, the 40 Gy isodose volume was the
only parameter predictive of late toxicity. Given that the
V40 of the bladder was increased by an average of 15.6%
(Figure 2), this likely suggests that patients receiving
ENI are simply closer to a threshold region for this par-
ameter. No change in sensitivity to hot spots was recog-
nized for the bladder as was noted for the rectum.
In contrast to the work of Sanguineti et al. [19], we
did not observe that the addition of ADT increased the
risk of late toxicity for patients treated without ENI.
However, any synergism between ADT and larger field
size, as suggested by the increased rate of rectal toxicity
observed in the WPRT +NHT arm of RTOG 94-13 [18],
cannot be ruled out. Another limitation of this study in-
cludes the inherent biases associated with its retrospect-
ive nature. Despite our well-defined inclusion criteria,
there was a trend towards a larger mean prostate volume
for patients who did not receive ENI, most likely as re-
sult of the increased use of neoadjuvant ADT in the ENI
group. The effect of this difference between the two
groups is likely minimal since daily alignment was to the
prostate-rectum interface and the prostate volume did
not appear to predict toxicity when analyzed independ-
ently. While a median follow-up of 33 months is likely ad-
equate to detect differences in rectal toxicity between the
two groups, urinary toxicity events continue to occur for
many years after the completion of therapy. Therefore, wecannot rule out differences in GU toxicity which may be-
come apparent with longer follow-up. Lastly, though the
addition of ENI increases radiation dose to the small
bowel we did not investigate the dosimetry of this struc-
ture as a predictor of toxicity within this cohort due to a
variety of reasons including significant interfraction vari-
ation and a lack of oral contrast at simulation to distin-
guish large and small bowel, which likely differ in terms of
radiosensitivity. We did investigate the size of the elective
nodal PTV, which is likely correlated to the volume of
small bowel irradiated, as a possible predictor of late tox-
icity but this was not statistically significant. Additionally,
the majority of late toxicity events were manifestations of
radiation proctitis.
With these limitations in mind, we recommend taking
added caution to minimize the volume of rectum receiv-
ing 100% or more of the prescription dose when ENI
and ADT are included as part of the treatment plan.
While V70 ≥ 3 cc was strongly predictive of worse tox-
icity in patients treated at our institutions, the particular
cut point for this isodose volume may vary by institution
as a result of differences in methods of treatment plan-
ning. As our collective experience with hypofractionated
prostate radiotherapy grows, and ongoing clinical trials
mature, treatment planning guidelines and normal tissue
complication probability modeling should be optimized
using multi-institutional outcomes data. Future work
should also confirm what appears to be sensitization of
the rectal mucosa to hot spots in the setting of larger
volumes receiving low and moderate doses in combin-
ation with concurrent ADT.
Conclusions
The addition of conventionally fractionated ENI to hypo-
fractionated prostate radiotherapy increases the rate of
late grade ≥ 2 lower GI toxicity when delivered with con-
current ADT. This appears to be due to sensitization of
the rectal mucosa to small volumes receiving the prescrip-
tion dose. We recommend added caution to minimize the
volume of rectum receiving 100% or more of the prescrip-
tion dose when ENI and ADT are included as part of the
treatment plan. Achieving V70 ≤ 3 cc in our population ap-
pears to further reduce the rate of late rectal toxicity.
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